文献速递乳腺癌

ATEMPT试验:T-DM1对比紫杉醇联合曲妥珠单抗辅助治疗I期HER2阳性乳腺癌

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
PubMed 文献 · J Clin Oncol · 2021-06-02

ATEMPT是一项随机临床试验,纳入497例I期HER2阳性乳腺癌患者,按3:1随机接受T-DM1或TH方案辅助治疗。主要终点为临床相关毒性(CRT)发生率和iDFS。

要点

  • T-DM1组与TH组临床相关毒性发生率无显著差异。
  • T-DM1组3年iDFS达97.8%,疗效良好。
  • T-DM1组神经病变和脱发更少,工作能力更好。

核心结论

  • 在I期HER2阳性乳腺癌患者中,辅助T-DM1治疗1年与优异的3年iDFS相关,但并未比TH方案减少临床相关毒性。

研究设计与样本

  • 随机临床试验,纳入497例经中心确认的I期HER2阳性乳腺癌患者,按3:1随机分配至T-DM1组(383例)或TH组(114例)。
  • T-DM1组接受T-DM1 3.6 mg/kg IV每3周一次共17周期;TH组接受紫杉醇80 mg/m2 IV联合曲妥珠单抗(负荷4 mg/kg后2 mg/kg)每周一次共12周,随后曲妥珠单抗6 mg/kg每3周一次共39周。
  • 共同主要终点为比较T-DM1组与TH组的临床相关毒性发生率,以及评估T-DM1组的iDFS。

主要发现

  • 患者报告结局显示,与TH组相比,T-DM1组神经病变和脱发更少,工作能力更好。

关键数值与推荐

  • T-DM1组3年iDFS为97.8%(95%CI 96.3-99.3)。

临床怎么用

  • 对于I期HER2阳性乳腺癌患者,辅助T-DM1治疗1年可获得优异的3年iDFS。
  • T-DM1并未比TH方案减少临床相关毒性,但患者报告结局显示神经病变和脱发更少、工作能力更好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). METHODS: Patients with stage I centrally confirmed HER2+ BC were randomly assigned 3:1 to T-DM1 or TH and received T-DM1 3.6 mg/kg IV every 3 weeks for 17 cycles or T 80 mg/m2 IV with H once every week × 12 weeks (4 mg/kg load →2 mg/kg), followed by H × 39 weeks (6 mg/kg once every 3 weeks). The co-primary objectives were to compare the incidence of clinically relevant toxicities (CRTs) in patients treated with T-DM1 versus TH and to evaluate iDFS in patients receiving T-DM1. RESULTS: The analysis population includes all 497 patients who initiated protocol therapy (383 T-DM1 and 114 TH). CRTs were experienced by 46% of patients on T-DM1 and 47% of patients on TH (P = .83). The 3-year iDFS for T-DM1 was 97.8% (95% CI, 96.3 to 99.3), which rejected the null hypothesis (P < .0001). Serially collected patient-reported outcomes indicated that patients treated with T-DM1 had less neuropathy and alopecia and better work productivity compared with patients on TH. CONCLUSION: Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tolaney SM, Tayob N, Dang C, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021. PMID: 34077270. doi:10.1200/JCO.20.03398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。